Developer docs
API playgroundTry for free, no card

Search company profiles

Valinor Discovery

Full company profile

uuid000h5xw

Namestring
Valinor Discovery
Legal namestring
Valinor Discovery
Company typeenum
Private
Founded yearint
2026
Descriptiontext

Valinor Discovery is a San Francisco-based, venture-backed AI biotechnology company building virtual patient foundation models to predict therapeutic response and disease progression in drug development. The platform ingests longitudinal, patient-derived multi-omics data — including whole genome sequencing, cfDNA methylation, transcriptomics, proteomics, MRI and amyloid PET imaging, histopathology, and structured clinical records — and embeds these modalities into a unified patient representation space. It then trains disease-specific models initially focused on neurology (Alzheimer's disease, multiple sclerosis, Parkinson's disease, ALS) and hematology (multiple myeloma, DLBCL, AML), where patient biology is least understood and clinical trial failure rates remain high. The intended use cases are patient stratification, responder identification, reverse translation, and prediction of progression events and standard-of-care response to improve clinical trial success rates.

The company generates proprietary datasets through its own data engine and through a strategic collaboration with Renew Biotechnologies, under which Valinor holds exclusive rights to train foundation models for biopharmaceutical customers on jointly-owned neurological datasets. Its go-to-market is enterprise B2B, targeting biopharmaceutical companies through direct field sales, research collaborations, co-development agreements, and licensing of its virtual patient models; pricing is not publicly disclosed. Valinor raised a $13M seed round in December 2025 led by CRV and Harpoon Ventures with Amino Collective, Pelion Venture Partners, and Mythos Ventures, and is backed by founders from Anthropic, Goodfire, and Mercor. The founding team — CEO Josh Pacini and COO/co-founder Zhanel Nugmanova — operates with 1-10 employees and is recruiting across machine learning, computational biology, and data engineering to scale the platform.

Short descriptiontext

Valinor Discovery builds AI-powered virtual patient foundation models from longitudinal multi-omics and clinical data to predict therapeutic response and improve clinical trial success rates for biopharmaceutical companies in neurology and hematology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug development, virtual patient modeling, multi-omics analytics, clinical trial optimization, biopharma AI platform
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-driven Drug Development Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Virtual Patient Model Licensing
TypeLicensing Royalties
Description

Valinor holds exclusive rights to train foundation models for biopharmaceutical customers using jointly-owned datasets. The company appears to generate revenue through licensing their ML models and data insights to drug development companies for patient selection, reverse translation, and therapeutic response prediction.

valinordiscovery.com
2Research Collaborations & Partnerships
TypeManaged Services
Description

The company pursues research collaborations with biotech partners, generating revenue through co-development agreements and strategic partnerships. Valinor also collaborates with Renew Biotechnologies for joint dataset ownership and model training.

valinordiscovery.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Valinor Discovery builds AI-powered virtual patient models trained on longitudinal multi-omics and clinical data to predict therapeutic response, patient selection, and disease progression for biopharmaceutical drug development. The company focuses initially on neurological disorders (Alzheimer's, Multiple Sclerosis, Parkinson's, ALS) and hematological malignancies (Multiple Myeloma, DLBCL, AML), licensing its foundation models and datasets to pharma and biotech customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Recovering prognostic subgroups learned entirely from multimodal data while stratifying risk better than clinical standards and genomic features alone in hematological malignancies
+3 more records
Product overview1 text field

Valinor Discovery offers a unified AI-powered platform centered on Virtual Patient Models for clinical drug development. The platform consists of three interconnected products: (1) a Proprietary Data Engine that generates patient-derived multi-omics datasets across disease timepoints; (2) Multi-Omics Integration Platform that unifies diverse data types (genomics, epigenomics, proteomics, imaging, clinical) into coherent patient representations; and (3) disease-specific Virtual Patient Models in Neurology (Alzheimer's, Parkinson's, ALS, Multiple Sclerosis) and Hematology (Multiple Myeloma, DLBCL, AML) that predict patient responses, disease progression, and therapeutic outcomes. The company also formed a strategic partnership with Renew Biotechnologies to generate the largest clinical multi-omics dataset for neurological disease modeling.

Product and service4 records
1Virtual Patient Models (Neurology)
CategoryAI-driven Drug Development Platform - Neurology
Description

AI-powered virtual patient models trained on longitudinal paired cfDNA methylation, proteomics, imaging, and clinical data across neurological disorders including ALS, Alzheimer's, Multiple Sclerosis, and Parkinson's. The model learns patient-level disease biology, outcome trajectories, and features driving disease progression for neurology drug developers.

2Virtual Patient Models (Hematology)
CategoryAI-driven Drug Development Platform - Hematology
Description

Virtual patient models trained on matched longitudinal datasets from patients with hematological malignancies, integrating clinical history, mutations, methylation, gene expression, and clinical endpoints to predict therapeutic response. Supports Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), and Acute Myeloid Leukemia (AML) for hematology and oncology drug developers.

3Proprietary Data Engine
CategoryAI-driven Drug Development Platform - Data Infrastructure
Description

A data generation platform that produces proprietary, patient-derived datasets collected across relevant disease timepoints using multi-omics and clinical assays including scRNAseq, Bulk RNAseq, Proteomics, cfDNA Methylation, Whole Genome Sequencing, Longitudinal Health Records, MRI, Amyloid PET Imaging, and Histopathology. Provides the longitudinal data foundation for training Valinor's virtual patient models.

4Multi-Omics Integration Platform
CategoryAI-driven Drug Development Platform - Interpretability
Description

A platform that embeds DNA, methylation, transcriptomics, proteomics, imaging, and structured clinical data into unified patient representations, capturing the heterogeneity of patient biology and enabling interpretable virtual patient modeling for biopharmaceutical drug development customers.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Strategic collaboration to generate the largest clinical multi-omics dataset for neurological disorders, combining Valinor's machine learning expertise with Renew's clinical laboratory infrastructure. The initiative will generate genomic and epigenomic data from thousands of patients with Alzheimer's, Parkinson's, ALS, and other neurological conditions using native-read sequencing. Renew provides clinical and sequencing infrastructure while Valinor applies machine learning to identify disease patterns and therapeutic response signatures. Datasets are jointly owned by both parties, with Valinor holding exclusive rights to train foundation models for biopharmaceutical customers.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Recursion is an AI-driven drug discovery company combining high-throughput biology, multi-omics, and machine learning to identify therapeutic targets and predict clinical outcomes. It is directly comparable to Valinor in using AI/multi-omics for pharma R&D, though it operates at greater scale with an integrated wet-lab platform.

TypeDirect peer
Description

Insitro uses machine learning on large-scale biological datasets (including multi-omics and patient-derived data) to predict clinical outcomes and accelerate drug discovery. Directly comparable to Valinor's virtual patient modeling and ML-driven pharma partnerships.

TypeDirect peer
Description

Exscientia applies AI to drug discovery and patient stratification, including precision medicine and clinical trial optimization work. It directly overlaps with Valinor's mission of using ML to improve clinical success rates and therapeutic response prediction.

TypeDirect peer
Description

Owkin builds AI models on multimodal patient data (genomics, imaging, clinical records) for biopharma R&D and clinical trial optimization, including federated learning approaches. Closely comparable to Valinor's multi-omics, longitudinal patient representation strategy.

TypeDirect peer
Description

Schrödinger combines physics-based computational chemistry with machine learning for drug discovery and predictive modeling. It is a direct peer in AI-driven pharma R&D, with broader computational chemistry scope but overlapping predictive-modeling philosophy.

6Tempus Labs
TypeBroad incumbent
Description

Tempus is a large precision medicine company that combines multi-omic profiling, clinical data, and AI to support pharma R&D and clinical decision-making. Comparable to Valinor in multi-omics + clinical data integration, though it operates as a broad incumbent across many therapeutic areas and services.

TypeDirect peer
Description

Iambic uses AI foundation models and physics-based simulation to predict molecular properties and clinical behavior. Directly comparable to Valinor's foundation model approach for drug development and patient response prediction.

TypeDirect peer
Description

Genesis Therapeutics applies AI and foundation models to small molecule drug discovery and therapeutic response prediction. It overlaps with Valinor in using ML to predict clinical outcomes and accelerate pharma partnerships.

TypeBroad incumbent
Description

Ginkgo Bioworks is a broad horizontal platform for cell engineering and synthetic biology, increasingly leveraging AI for predictive modeling in pharma and biotech. Comparable to Valinor as a large, well-capitalized AI-biology platform though operating across a broader synthetic biology scope.

TypeEmerging player
Description

Cradle applies generative AI/ML models to protein engineering and drug discovery. Comparable to Valinor as an emerging AI-biotech applying foundation model approaches to pharma R&D, though focused earlier in the discovery pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valinor Discovery

AI-driven Drug Development Platformvalinordiscovery.com

Valinor Discovery builds AI-powered virtual patient foundation models from longitudinal multi-omics and clinical data to predict therapeutic response and improve clinical trial success rates for biopharmaceutical companies in neurology and hematology.

What Valinor Discovery does

Valinor Discovery is a San Francisco-based, venture-backed AI biotechnology company building virtual patient foundation models to predict therapeutic response and disease progression in drug development. The platform ingests longitudinal, patient-derived multi-omics data — including whole genome sequencing, cfDNA methylation, transcriptomics, proteomics, MRI and amyloid PET imaging, histopathology, and structured clinical records — and embeds these modalities into a unified patient representation space. It then trains disease-specific models initially focused on neurology (Alzheimer's disease, multiple sclerosis, Parkinson's disease, ALS) and hematology (multiple myeloma, DLBCL, AML), where patient biology is least understood and clinical trial failure rates remain high. The intended use cases are patient stratification, responder identification, reverse translation, and prediction of progression events and standard-of-care response to improve clinical trial success rates.

The company generates proprietary datasets through its own data engine and through a strategic collaboration with Renew Biotechnologies, under which Valinor holds exclusive rights to train foundation models for biopharmaceutical customers on jointly-owned neurological datasets. Its go-to-market is enterprise B2B, targeting biopharmaceutical companies through direct field sales, research collaborations, co-development agreements, and licensing of its virtual patient models; pricing is not publicly disclosed. Valinor raised a $13M seed round in December 2025 led by CRV and Harpoon Ventures with Amino Collective, Pelion Venture Partners, and Mythos Ventures, and is backed by founders from Anthropic, Goodfire, and Mercor. The founding team — CEO Josh Pacini and COO/co-founder Zhanel Nugmanova — operates with 1-10 employees and is recruiting across machine learning, computational biology, and data engineering to scale the platform.

Valinor Discovery firmographics

Firmographics
Name
Valinor Discovery
Legal name
Valinor Discovery
Website
https://valinordiscovery.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
1–10 employees
Short description
Valinor Discovery builds AI-powered virtual patient foundation models from longitudinal multi-omics and clinical data to predict therapeutic response and improve clinical trial success rates for biopharmaceutical companies in neurology and hematology.
Ownership category
akta.pro rank

Valinor Discovery industry classification

Industry
Product category
AI-driven Drug Development Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug development
  • Virtual patient modeling
  • Multi-omics analytics
  • Clinical trial optimization
  • Biopharma AI platform

Where Valinor Discovery is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Valinor Discovery business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Virtual Patient Model Licensing: Valinor holds exclusive rights to train foundation models for biopharmaceutical customers using jointly-owned datasets. The company appears to generate revenue through licensing their ML models and data insights to drug development companies for patient selection, reverse translation, and therapeutic response prediction.
  2. Research Collaborations & Partnerships: The company pursues research collaborations with biotech partners, generating revenue through co-development agreements and strategic partnerships. Valinor also collaborates with Renew Biotechnologies for joint dataset ownership and model training.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Valinor Discovery product offering

Product offering

Core offering

Valinor Discovery builds AI-powered virtual patient models trained on longitudinal multi-omics and clinical data to predict therapeutic response, patient selection, and disease progression for biopharmaceutical drug development. The company focuses initially on neurological disorders (Alzheimer's, Multiple Sclerosis, Parkinson's, ALS) and hematological malignancies (Multiple Myeloma, DLBCL, AML), licensing its foundation models and datasets to pharma and biotech customers.

Product overview

Valinor Discovery offers a unified AI-powered platform centered on Virtual Patient Models for clinical drug development. The platform consists of three interconnected products: (1) a Proprietary Data Engine that generates patient-derived multi-omics datasets across disease timepoints; (2) Multi-Omics Integration Platform that unifies diverse data types (genomics, epigenomics, proteomics, imaging, clinical) into coherent patient representations; and (3) disease-specific Virtual Patient Models in Neurology (Alzheimer's, Parkinson's, ALS, Multiple Sclerosis) and Hematology (Multiple Myeloma, DLBCL, AML) that predict patient responses, disease progression, and therapeutic outcomes. The company also formed a strategic partnership with Renew Biotechnologies to generate the largest clinical multi-omics dataset for neurological disease modeling.

Differentiator

Problem solved

Functional benefit

Products and services

  • Virtual Patient Models (Neurology) AI-powered virtual patient models trained on longitudinal paired cfDNA methylation, proteomics, imaging, and clinical data across neurological disorders including ALS, Alzheimer's, Multiple Sclerosis, and Parkinson's. The model learns patient-level disease biology, outcome trajectories, and features driving disease progression for neurology drug developers.
  • Virtual Patient Models (Hematology) Virtual patient models trained on matched longitudinal datasets from patients with hematological malignancies, integrating clinical history, mutations, methylation, gene expression, and clinical endpoints to predict therapeutic response. Supports Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), and Acute Myeloid Leukemia (AML) for hematology and oncology drug developers.
  • Proprietary Data Engine A data generation platform that produces proprietary, patient-derived datasets collected across relevant disease timepoints using multi-omics and clinical assays including scRNAseq, Bulk RNAseq, Proteomics, cfDNA Methylation, Whole Genome Sequencing, Longitudinal Health Records, MRI, Amyloid PET Imaging, and Histopathology. Provides the longitudinal data foundation for training Valinor's virtual patient models.
  • Multi-Omics Integration Platform A platform that embeds DNA, methylation, transcriptomics, proteomics, imaging, and structured clinical data into unified patient representations, capturing the heterogeneity of patient biology and enabling interpretable virtual patient modeling for biopharmaceutical drug development customers.

Quantifiable outcome

  • Recovering prognostic subgroups learned entirely from multimodal data while stratifying risk better than clinical standards and genomic features alone in hematological malignancies
  • +3 more outcomes

Companies that use Valinor Discovery

Customer profile

Segments3 records

Ideal customer profiles3 records

Valinor Discovery technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Valinor Discovery partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Renew BiotechnologiescoreStrategic or Co-development Partner · 24 February 2026Strategic collaboration to generate the largest clinical multi-omics dataset for neurological disorders, combining Valinor's machine learning expertise with Renew's clinical laboratory infrastructure. The initiative will generate genomic and epigenomic data from thousands of patients with Alzheimer's, Parkinson's, ALS, and other neurological conditions using native-read sequencing. Renew provides clinical and sequencing infrastructure while Valinor applies machine learning to identify disease patterns and therapeutic response signatures. Datasets are jointly owned by both parties, with Valinor holding exclusive rights to train foundation models for biopharmaceutical customers.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Valinor Discovery competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company combining high-throughput biology, multi-omics, and machine learning to identify therapeutic targets and predict clinical outcomes. It is directly comparable to Valinor in using AI/multi-omics for pharma R&D, though it operates at greater scale with an integrated wet-lab platform.
  • Insitro: Insitro uses machine learning on large-scale biological datasets (including multi-omics and patient-derived data) to predict clinical outcomes and accelerate drug discovery. Directly comparable to Valinor's virtual patient modeling and ML-driven pharma partnerships.
  • Exscientia: Exscientia applies AI to drug discovery and patient stratification, including precision medicine and clinical trial optimization work. It directly overlaps with Valinor's mission of using ML to improve clinical success rates and therapeutic response prediction.
  • Owkin: Owkin builds AI models on multimodal patient data (genomics, imaging, clinical records) for biopharma R&D and clinical trial optimization, including federated learning approaches. Closely comparable to Valinor's multi-omics, longitudinal patient representation strategy.
  • Schrödinger: Schrödinger combines physics-based computational chemistry with machine learning for drug discovery and predictive modeling. It is a direct peer in AI-driven pharma R&D, with broader computational chemistry scope but overlapping predictive-modeling philosophy.
  • Iambic Therapeutics (formerly Entos): Iambic uses AI foundation models and physics-based simulation to predict molecular properties and clinical behavior. Directly comparable to Valinor's foundation model approach for drug development and patient response prediction.
  • Genesis Therapeutics: Genesis Therapeutics applies AI and foundation models to small molecule drug discovery and therapeutic response prediction. It overlaps with Valinor in using ML to predict clinical outcomes and accelerate pharma partnerships.

Broad incumbents

  • Tempus Labs: Tempus is a large precision medicine company that combines multi-omic profiling, clinical data, and AI to support pharma R&D and clinical decision-making. Comparable to Valinor in multi-omics + clinical data integration, though it operates as a broad incumbent across many therapeutic areas and services.
  • Ginkgo Bioworks: Ginkgo Bioworks is a broad horizontal platform for cell engineering and synthetic biology, increasingly leveraging AI for predictive modeling in pharma and biotech. Comparable to Valinor as a large, well-capitalized AI-biology platform though operating across a broader synthetic biology scope.

Emerging players

  • Cradle Bio: Cradle applies generative AI/ML models to protein engineering and drug discovery. Comparable to Valinor as an emerging AI-biotech applying foundation model approaches to pharma R&D, though focused earlier in the discovery pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Valinor Discovery social profiles

Digital presence

Valinor Discovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valinor Discovery leadership team

Management profile

Number of profiles

Profiles2 records

Valinor Discovery funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valinor Discovery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valinor Discovery

What does Valinor Discovery do?

Valinor Discovery builds AI-powered virtual patient models trained on longitudinal multi-omics and clinical data to predict therapeutic response, patient selection, and disease progression for biopharmaceutical drug development. The company focuses initially on neurological disorders (Alzheimer's, Multiple Sclerosis, Parkinson's, ALS) and hematological malignancies (Multiple Myeloma, DLBCL, AML), licensing its foundation models and datasets to pharma and biotech customers.

Is Valinor Discovery a public or private company?

Valinor Discovery is a private company. It is classified as venture growth investor backed and is currently operating.

When was Valinor Discovery founded?

Valinor Discovery was founded in 2026. It employs 1 to 10 people.

Where is Valinor Discovery based?

Valinor Discovery is headquartered in San Francisco, United States, in the North America region.

How does Valinor Discovery make money?

Two revenue lines are on record. Virtual Patient Model Licensing is the primary driver. The others are research Collaborations & Partnerships.

Who are Valinor Discovery's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Exscientia, Owkin, Schrödinger, Iambic Therapeutics (formerly Entos) and Genesis Therapeutics. Broad incumbents are Tempus Labs and Ginkgo Bioworks. Cradle Bio is listed as an emerging player.

Does Valinor Discovery have an API?

No public API is recorded for Valinor Discovery.

What industry is Valinor Discovery in?

Valinor Discovery's product category is AI-driven Drug Development Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Scientist LiveValinor and Renew partner to generate clinical multi-omics dataset for neurological disease model developmentValinor Discovery and Renew Biotechnologies have partnered to generate a comprehensive clinical multi-omics dataset focused on neurological disorders, including Parkinson's disease, ALS, and Alzheimer’s, to improve disease prediction and therapeutic responses. The collaboration leverages Renew's clinical and sequencing infrastructure with Valinor's machine learning models to identify disease patterns. The initiative aims to enhance decision-making and reduce costs in neurology drug development, with datasets jointly owned by both parties.BioSpaceValinor and Renew Launch Partnership to Generate Largest Clinical Multi-Omics Dataset for Neurological Disease Model DevelopmentValinor Discovery and Renew Biotechnologies announced a strategic collaboration to generate the largest clinical multi-omics dataset to date for neurological disorders, including Alzheimer's disease, Parkinson's disease, and ALS. The partnership combines Renew's clinical laboratory infrastructure and multi-omics data generation capabilities with Valinor's proprietary machine learning architectures to develop predictive models for disease onset and therapeutic responses. The companies will jointly own the resulting datasets, with Valinor serving as the exclusive AI partner authorized to train models, aiming to accelerate biopharma R&D and reduce development costs in neurology.PR NewswireValinor and Renew Launch Partnership to Generate Largest Clinical Multi-Omics Dataset for Neurological Disease Model DevelopmentValinor Discovery and Renew Biotechnologies announced a strategic collaboration to generate the largest clinical multi-omics dataset for neurological disorders. The initiative aims to improve prediction of disease onset and therapeutic responses using advanced machine learning and high-resolution data from patients with diseases like Alzheimer's, Parkinson's, and ALS.PR NewswireValinor and Renew Launch Partnership to Generate Largest Clinical Multi-Omics Dataset for Neurological Disease Model DevelopmentValinor Discovery and Renew Biotechnologies announced a strategic collaboration to generate the largest clinical multi-omics dataset for neurological disorders, combining Valinor's machine learning expertise with Renew's clinical laboratory infrastructure. The initiative will generate genomic and epigenomic data from thousands of patients with Alzheimer's, Parkinson's, ALS, and other neurological conditions to support predictive modeling and biopharma decision-making. The partnership aims to address the limited availability of clinically relevant human data that has hindered neurological drug development, with the goal of reducing R&D costs and accelerating programs toward clinical milestones.GenomeWebValinor Discovery, Renew Biotech Partner for Multiomics-Based Neurological Disease ModelingValinor Discovery has partnered with Renew Biotechnologies to build a clinical multiomics dataset for use in neurological disease modeling, including Alzheimer's, Parkinson's, and ALS. Under the agreement, Renew will generate genomic and epigenomic data from patient samples using native-read sequencing, while Valinor will apply machine learning to identify disease patterns and therapeutic response signatures. The companies will jointly own the resulting data, with Valinor holding exclusive rights to train foundation models for biopharmaceutical customers, and Valinor previously raised $13 million in seed funding in late 2025.Precedence ResearchOmics-Based Clinical Trials Market Size to Hit USD 78.03 Billion by 2035The global omics-based clinical trials market is valued at USD 35.71 billion in 2025 and projected to reach USD 78.03 billion by 2035, expanding at a CAGR of 8.13%, driven by precision medicine adoption and multi-omics integration. North America held over 38% market share in 2025, while the Asia-Pacific region is expected to grow fastest, with China leading the region through government-sponsored genomics programs. Recent developments include Valinor securing USD 13 million in seed funding in December 2025 for AI-driven multi-omic analysis, and a January 2025 partnership between Nvidia and Illumina to apply genomics and AI technologies in drug discovery.Pulse 2.0Valinor: $13 Million Seed Funding Raised To Boost Clinical Trial Success With Multimodal Machine LearningValinor, a San Francisco-based AI company, has announced it raised $13 million in seed funding to enhance its machine-learning-driven platform aimed at improving clinical trial outcomes. The funding round was led by CRV, Harpoon Ventures, Amino Collective, and Pelion Venture Partners, which will help Valinor expand its datasets and AI models for better patient selection in clinical trials. The company's technology is designed to facilitate faster and more targeted enrollment decisions for drug developers.Pulse 2.0Valinor Raises $13 Million To Advance AI-Driven Patient Selection For Clinical TrialsValinor, a San Francisco-based AI company focused on improving clinical trial outcomes, has raised $13 million in seed funding to expand its proprietary machine learning platform for patient selection. The financing was led by CRV with participation from Harpoon Ventures, Amino Collective, Pelion Venture Partners, and a group of angel investors. The platform analyzes matched multi-omic data and real-world clinical outcomes to predict patient response to therapies, with the goal of reducing trial failure rates, lowering R&D costs, and accelerating the delivery of new treatments to patients.FinSMEsValinor Raises $13M in FundingValinor, a San Francisco AI company, raised $13M in seed funding led by CRV, Harpoon Ventures, Amino Collective, and Pelion Venture Partners. The company will use the funds to expand its proprietary datasets and recruit additional staff. It aims to reduce trial-and-error in drug development by predicting patient response.Venture Capital Access OnlineValinor Raises $13 Million to Increase Clinical Trial Success Rates with Proprietary ML ModelsValinor, a San Francisco-based AI company, announced $13 million in seed funding led by CRV, Harpoon Ventures, Amino Collective, and Pelion Venture Partners, with additional participation from angel investors. The company will use the funding to expand its proprietary matched omics and clinical outcome datasets and recruit machine learning talent to advance its multimodal platform that predicts patient response in clinical trials. The technology aims to help pharmaceutical partners improve clinical trial success rates, reduce R&D costs, and accelerate drug development timelines.